Compile Data Set for Download or QSAR
Report error Found 198 Enz. Inhib. hit(s) with all data for entry = 1457
TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323933(US10189809, Compound I-278)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323935(US10189809, Compound I-205)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323934(US10189809, Compound I-206)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323920(US10189809, Compound I-219)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323923(US10189809, Compound I-216)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323922(US10189809, Compound I-217)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323925(US10189809, Compound I-214)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323924(US10189809, Compound I-215)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323927(US10189809, Compound I-212)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323946(US10189809, Compound I-193)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323948(US10189809, Compound I-191)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323947(US10189809, Compound I-192)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323950(US10189809, Compound I-189)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323949(US10189809, Compound I-190)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323952(US10189809, Compound I-187)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323951(US10189809, Compound I-188)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323937(US10189809, Compound I-202)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323940(US10189809, Compound I-198)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323944(US10189809, Compound I-195)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323943(US10189809, Compound I-196)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323962(US10189809, Compound I-177)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323961(US10189809, Compound I-178)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323964(US10189809, Compound I-175)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323963(US10189809, Compound I-176)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323965(US10189809, Compound I-174)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323969(US10189809, Compound I-171)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323968(US10189809, Compound I-172)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323954(US10189809, Compound I-185)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323953(US10189809, Compound I-186)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323956(US10189809, Compound I-183)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323955(US10189809, Compound I-184)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323958(US10189809, Compound I-181)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323957(US10189809, Compound I-182)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323960(US10189809, Compound I-179)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323959(US10189809, Compound I-180)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323982(US10189809, Compound I-156)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323984(US10189809, Compound I-153)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323983(US10189809, Compound I-155)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323986(US10189809, Compound I-151)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323985(US10189809, Compound I-152)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323987(US10189809, Compound I-150)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323971(US10189809, Compound I-168)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323970(US10189809, Compound I-169)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323973(US10189809, Compound I-166)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323972(US10189809, Compound I-167)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323976(US10189809, Compound I-162)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323975(US10189809, Compound I-165)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323980(US10189809, Compound I-160)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323977(US10189809, Compound I-161)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323854(US10189809, Compound I-125)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/25/2019
Entry Details
US Patent

Displayed 1 to 50 (of 198 total ) | Next | Last >>
Jump to: